The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Key Takeaways Zepbound helped patients lose 50 pounds, compared to 33 pounds with WegovyThe study showed Zepbound users lost ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy. Side effects for ... People taking Zepbound, Eli Lilly’s obesity drug, lost almost ...

Eli Lilly & Co.’s obesity ... About four-fifths of Zepbound patients lost at least 10%, compared to about three-fifths of Wegovy patients. Side effects were similar, though far more Zepbound ...

face a new challenge of their own as federal regulators crack down on the cheaper versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound that have become a big part of the companies’ sales.